Registry-based, Prospective, Observational Studies to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Migraine Treatments, Including Galcanezumab

Compare maternal, fetal and infant outcomes among pregnant women with migraine exposed to galcanezumab to those exposed or not exposed to other migraine medications. There is a need to study utilization and safety of these medications before/during pregnancy since data on outcomes of pregnancies exposed to galcanezumab is limited.